BCL2 and B-cell chronic lymphocytic leukemia: This was followed by the introduction of a BCL-2-specific inhibitor, ABT-199 (Venetoclax), which has received approval for treating refractory chronic lymphocytic leukemia (CLL), where BCL-2 addiction is a key feature in the pathogenesis of the disease.